Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
248 hedge funds and large institutions have $6.78B invested in Karuna Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 108 increasing their positions, 74 reducing their positions, and 42 closing their positions.
92% more call options, than puts
Call options by funds: $87.5M | Put options by funds: $45.5M
46% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 74
4% less funds holding
Funds holding: 257 → 248 (-9)
11% less capital invested
Capital invested by funds: $7.65B → $6.78B (-$867M)
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
17% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$150M |
| 2 |
GA
General Atlantic
New York
|
+$64.6M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$49.2M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$37.5M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$36.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$172M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$41M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$31.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$30.4M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$28.5M |
KRTX Hedge Fund Activity: Q4 2022 in Review
248 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q4 2022, worth a combined $6.78B — down 11% from $7.65B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of KRTX and 35 opened new positions — a net loss of 7 holders — while 74 trimmed existing stakes and 108 added.
The largest buyer was Fidelity Investments, adding an estimated $150M. The largest seller was Arch Venture Management, cutting an estimated $172M.
- 248 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q4 2022, down from 257 in Q3 2022.
- Funds reported $6.78B of Karuna Therapeutics, Inc. Common Stock stock for Q4 2022, down 11% quarter-over-quarter.
- 35 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q4 2022 and 42 closed out, a net change of -7 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q4 2022 was Fidelity Investments, an estimated $150M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q4 2022 was Arch Venture Management, an estimated $172M sold.
Based on aggregated 13F filings for Q4 2022.